share_log

Dare Bioscience Analyst Ratings

Benzinga Analyst Ratings ·  Dec 13, 2022 06:12
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
12/13/2022 652.77% HC Wainwright & Co. $6 → $7 Maintains Buy
12/01/2022 545.23% JonesTrading → $6 Initiates Coverage On → Buy
04/01/2022 545.23% HC Wainwright & Co. $5 → $6 Maintains Buy
06/30/2021 1082.92% Roth Capital $9 → $11 Maintains Buy
12/18/2020 437.69% HC Wainwright & Co. → $5 Initiates Coverage On → Buy
04/28/2020 706.54% Brookline Capital → $7.5 Initiates Coverage On → Buy
08/17/2018 222.62% Maxim Group → $3 Initiates Coverage On → Buy

What is the target price for Dare Bioscience (DARE)?

The latest price target for Dare Bioscience (NASDAQ: DARE) was reported by HC Wainwright & Co. on December 13, 2022. The analyst firm set a price target for $7.00 expecting DARE to rise to within 12 months (a possible 652.77% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Dare Bioscience (DARE)?

The latest analyst rating for Dare Bioscience (NASDAQ: DARE) was provided by HC Wainwright & Co., and Dare Bioscience maintained their buy rating.

When is the next analyst rating going to be posted or updated for Dare Bioscience (DARE)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dare Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dare Bioscience was filed on December 13, 2022 so you should expect the next rating to be made available sometime around December 13, 2023.

Is the Analyst Rating Dare Bioscience (DARE) correct?

While ratings are subjective and will change, the latest Dare Bioscience (DARE) rating was a maintained with a price target of $6.00 to $7.00. The current price Dare Bioscience (DARE) is trading at is $0.93, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment